Pacer Advisors Inc. Increases Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Pacer Advisors Inc. increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,724 shares of the company’s stock after purchasing an additional 1,315 shares during the period. Pacer Advisors Inc.’s holdings in IDEXX Laboratories were worth $4,276,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Altshuler Shaham Ltd purchased a new stake in IDEXX Laboratories during the second quarter valued at about $28,000. Cornerstone Advisors Inc. grew its position in IDEXX Laboratories by 100.0% during the second quarter. Cornerstone Advisors Inc. now owns 140 shares of the company’s stock valued at $39,000 after acquiring an additional 70 shares during the period. Captrust Financial Advisors grew its position in IDEXX Laboratories by 32.5% during the second quarter. Captrust Financial Advisors now owns 151 shares of the company’s stock valued at $42,000 after acquiring an additional 37 shares during the period. Monetary Management Group Inc. purchased a new stake in IDEXX Laboratories during the first quarter valued at about $45,000. Finally, Personal Wealth Partners purchased a new stake in IDEXX Laboratories during the second quarter valued at about $52,000. 86.69% of the stock is owned by institutional investors and hedge funds.

In other IDEXX Laboratories news, Director Rebecca M. Henderson sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $271.17, for a total transaction of $1,084,680.00. Following the sale, the director now owns 14,696 shares in the company, valued at $3,985,114.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Chairman Jonathan W. Ayers sold 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $262.26, for a total value of $5,245,200.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 73,305 shares of company stock worth $19,402,442. Insiders own 2.70% of the company’s stock.

A number of brokerages have commented on IDXX. Stifel Nicolaus boosted their price objective on IDEXX Laboratories from $255.00 to $295.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. BidaskClub upgraded IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Saturday, September 21st. Credit Suisse Group boosted their price objective on IDEXX Laboratories from $282.00 to $293.00 and gave the stock an “outperform” rating in a research note on Friday, August 16th. Bank of America set a $300.00 price objective on IDEXX Laboratories and gave the stock a “buy” rating in a research note on Friday, June 21st. Finally, Goldman Sachs Group began coverage on IDEXX Laboratories in a research note on Monday, September 9th. They set a “neutral” rating and a $277.00 price objective on the stock. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. IDEXX Laboratories has an average rating of “Buy” and an average target price of $285.29.

NASDAQ:IDXX opened at $276.80 on Friday. The company has a debt-to-equity ratio of 4.49, a quick ratio of 0.83 and a current ratio of 1.15. IDEXX Laboratories, Inc. has a one year low of $176.11 and a one year high of $292.17. The business’s 50-day simple moving average is $276.32 and its 200 day simple moving average is $261.74. The stock has a market cap of $23.83 billion, a price-to-earnings ratio of 64.98 and a beta of 0.82.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Thursday, August 1st. The company reported $1.43 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.37 by $0.06. IDEXX Laboratories had a return on equity of 765.45% and a net margin of 17.78%. The business had revenue of $620.10 million for the quarter, compared to analysts’ expectations of $627.10 million. During the same quarter in the previous year, the firm posted $1.23 earnings per share. The company’s revenue was up 6.8% compared to the same quarter last year. On average, equities research analysts predict that IDEXX Laboratories, Inc. will post 4.86 EPS for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc, together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments.

Read More: What is a Market Correction?

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.